Neuroprotection by metabotropic glutamate receptor agonists: LY354740, LY379268 and LY389795

European Journal of Pharmacology

Volumn 377, Issue 2-3, 1999, Pages 155-165

  Kingston, Ann E ^a   O'Neill, Michael J ^a   Lam, Amy ^a   Bales, Kelly R ^a   Monn, James A ^a   Schoepp, Darryle D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Excitotoxicity; Glutamate; Group II mGlu receptor agonist

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; DIZOCILPINE; DNA FRAGMENT; EGLUMETAD; EXCITOTOXIN; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; KAINIC ACID; LACTATE DEHYDROGENASE; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; STAUROSPORINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN ISCHEMIA; BRAIN NERVE CELL; CELL DEATH; CONTROLLED STUDY; ENZYME RELEASE; FETUS; GERBIL; INTRAPERITONEAL DRUG ADMINISTRATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

AMINO ACIDS; ANIMALS; BICYCLO COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELLS, CULTURED; CEREBRAL CORTEX; DNA FRAGMENTATION; ENZYME INHIBITORS; EXCITATORY AMINO ACID AGONISTS; GERBILLINAE; KAINIC ACID; L-LACTATE DEHYDROGENASE; N-METHYLASPARTATE; NEUROPROTECTIVE AGENTS; RATS; STAUROSPORINE;

EID: 0032791811     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00397-0     Document Type: Article

References (47)

1. Altemus K.L., Colwell C.S., Levine M.S. Modulation of excitotoxic damage in the neostriatum by metabotropic glutamate receptor. Soc. Neurosci. Abstr. 21:1995;217.6.
2. Battaglia G., Monn J.A., Schoepp D.D. In vivo inhibition of veratridine evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci. Lett. 229:1997;161-164.
3. Battaglia G., Bruno V., Ngomba R.T., di Grezia R., Copani A., Nicoletti F. Selective activation of group-II metabotropic glutamate receptors is protective against excitotoxic neuronal death. Eur. J. Pharmacol. 356:1998;271-274.
4. Bond A., O'Neill M.J., Hicks C.A., Monn J.A., Lodge D. Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia. NeuroReport. 9:1998;1191-1193.
5. Boxer P.A., Bigge C.F. Mechanisms of neuronal cell injury/death and targets for drug intervention. Drug Dis. Today. 2:1997;219-228.
6. Bruno V., Copani A., Battaglia G., Raffaele R., Shinozaki H., Nicoletti F. Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal cell death. Eur. J. Pharmacol. 256:1994;109-112.
7. Bruno V., Battaglia G., Copani A., Giffard R.G., Raciti G., Raffaele R., Shinozaki H., Nicoletti F. Activation of class II or class III metabotropic glutamate receptors protects cultured cortical neurons against excitotoxic degeneration. Eur. J. Neurosci. 7:1995;1906-1913.
8. Bruno V., Sureda F.X., Storto M., Casabona G., Caruso A., Knopfel T., Kuhn R., Nicoletti F. The neuroprotective activity of group II metabotropic glutamate receptors requires new protein synthesis and involves a glial-neuronal signalling. J. Neurosci. 17:1997;1891-1897.
9. Bruno V., Battaglia G., Casabona G., Copani A., Caciagli F., Nicoletti F. Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor beta. J. Neurosci. 18:1998;9594-9600.
10. Buisson A., Choi D.W. The inhibitory mGluR agonist, S-4-carboxy-3-hydroxyphenylglycine selectively attenuates NMDA neurotoxicity and oxygen-glucose deprivation-induced neuronal death. Neuropharmacology. 34:1995;1081-1087.
11. Buisson A., Yu S.P., Choi D.W. Effect of glutamate receptor agonists onexcitotoxic and apoptotic cell death in murine cortical cell culture. Soc. Neurosci. Abstr. 20:1994;198.5.
12. Buisson A., Yu S.P., Choi D.W. DCG-IV selectively attenuates rapidly triggered NMDA-induced neurotoxicity in cortical neurons. Eur. J. Neurosci. 8:1996;138-143.
13. Butcher S.P., Bullock R., Graham D.I., McCulloch J. Correlation between amino-acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion. Stroke. 21:1990;1727-1733.
14. Chavis P., Nooney J.M., Bockaert J., Fagni L., Feltz A., Bossu J.L. Facilitatory coupling between a glutamate metabotropic receptor and dihydropyridine-sensitive calcium channels in cultured cerebellar granule cells. J. Neurosci. 15:1995;135-143.
15. Chiamulera C., Albertini P., Valerio E., Reggiani A. Activation of metabotropic receptors has a neuroprotective effect in a rodent model of focal ischaemia. Eur. J. Pharmacol. 216:1992;335-336.
16. Choi D.W. Ionic dependence of glutamate neurotoxicity. J. Neurosci. 7:1987;369-379.
17. Choi D.W. Glutamate neurotoxicity and diseases of the central nervous system. Neuron. 1:1988;623-634.
18. Choi D.W., Hartley D.M. Calcium and glutamate-induced cortical neuronal death. Research Publications - Association for Research in Nervous and Mental Disease. 21:1993;23-34.
19. Conn P.J., Pin J.-P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37:1997;205-237.
20. Copani A., Bruno V., Battaglia G., Leanza G., Pellitteri R., Russo A., Stanzani S., Nicoletti F. Activation of metabotropic glutamate receptors protects neurons against apoptosis induced by beta-amyloid peptide. Mol. Pharmacol. 47:1995;890-897.
21. Du Y., Bales K.R., Dodel R.C., Hamilton-Byrd E., Horn J.W., Czilli D.L., Simmons L.K., Ni B., Paul S.M. Activation of a caspase 3-related cysteine protease is required for glutamate mediated apoptosis of cultures cerebellar granule neurons. Proc. Natl. Acad. Sci. 94:1997;11657-11662.
22. Fredholm B.B. Adenosine and neuroprotection. Int. Rev. Neurobiol. 40:1997;259-280.
23. Gereau R.W., Conn J.P. Potentiation of cAMP responses by metabotropic glutamate receptors depresses excitatory synaptic transmission by a kinase independent mechanism. Neuron. 12:1994;1121-1129.
24. Globus M.Y., Busto R., Dietrich W.D., Martinez E., Valdes I., Ginsberg M.D. Intra-ischemic extracellular release of dopamine and glutamate is associated with striatal vulnerability to ischemia. Neurosci. Lett. 91:1988;36-40.
25. Huang P., Plunkett W. A quantitative assay for fragmented DNA in apoptotic cells. Analytical Biochemistry. 207:1992;163-167.
26. Kingston A.E., Ornstein P.L., Wright R.A., Johnson B.G., Mayne N.G., Burnett J.P., Belagaje R., Wu S., Schoepp D.D. LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology. 37:1998;1-12.
27. Koh J.-Y., Gwag B.J., Sensi S.L., Canzoniero L.M.T., Demaro J., Czernansky C., Choi D.W. Staurosporine-induced neuronal apoptosis. Exp. Neurol. 135:1995;153-159.
28. Logan M., Sweeney M.I. Adenosine A1 receptor activation preferentially protects cultured cerebellar neurons versus astrocytes against hypoxia-induced death. Mol. Chem. Neuropathol. 31:1997;119-133.
29. Maiese K., Greenberg R., Boccone L., Swiriduk M. Activation of metabotropic glutamate receptors is neuroprotective during nitric oxide toxicity in primary hippocampal neurons of rats. Neurosci. Lett. 194:1994;173-176.
30. May P.C., Robison P.M. Cyclothiazide treatment unmasks AMPA excitotoxicity in rat primary hippocampal cultures. J. Neurochem. 60:1993;1171-1174.
31. McDonald J.W., Schoepp D.D. The metabotropic excitatory amino acid receptor agonist 1S,3R ACPD selectively potentiates N-methyl-D-aspartate induced brain injury. Eur. J. Pharmacol. 215:1992;353-354.
32. McDonald J.W., Fix A.S., Tizzano J.P., Schoepp D.D. Seizures and brain injury in neonatal rats induced by 1S,3R-ACPD, a metabotropic glutamate receptor agonist. J. Neurosci. 13:1993;4445-4455.
33. Monn J.A., Valli M.J., Massey S.M., Wright R.A., Salhoff C.R., Johnson B.G., Howe T., Alt C.A., Rhodes G.A., Robey R.L., Griffey K.R., Tizzano J.P., Kallman M.J., Helton D.R., Schoepp D.D. Design, synthesis and pharmacological characterisation of (+)-2-aminobicylco[3.1.0]hexane-2,6-dicarboxylate: a potent selective, systemically active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J. Med. Chem. 40:1997;528-537.
34. Monn J.A., Valli M.J., Massey S.M., Hansen M.M., Harkness A.R., Grutsch J.L. Jr., Wright R.A., Johnson B.G., Andis S.L., Kingston A.E., Tomlinson R., Lewis R., Griffey K.R., Tizzano J.P., Schoepp D.D. Synthesis, pharmacological characterization and molecular modeling of heterobicyclic amino acids related to LY354740: identification of LY379268 and LY389795: two new potent, selective and systemically active agonists for group II metabotropic glutamate receptors. J. Med. Chem. 42:1999;1027-1040.
35. Orlando L.R., Standaert D.G., Cha H., Penney J.B., Young A.B. Metabotropic receptors in excitotoxicity: (S)-4C3HPG protects against striatal quinolinic acid lesions. Soc. Neurosci. Abstr. 21:1995;529.19.
36. Rose, K., Goldberg, M.P., Choi, D.W., 1993. Cytotoxicity in murine cortical cell culture. In: Tyson, C.A., Frazier, J.M. (Eds.), In Vitro Biological Methods. Academic Press, San Diego, CA, pp. 46-60.
37. Schoepp D.D., Conn J.P. Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol. Sci. 14:1993;13-20.
38. Schoepp D.D., Johnson B.G., Wright R.A., Salhoff C.R., Mayne N.G., Wu S., Cockerham S.L., Burnett J.P., Belegaje R., Bleakman D., Monn J.A. LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors. Neuropharmacology. 36:1997;1-11.
39. Shinozaki, H., Ishida, M., Miyamoto, M., Kwak, S., 1994. Sedative and neuroprotective actions of potent and selective agonists for metabotropic glutamate receptors. In: Excitatory Amino Acids: Approaches to Clinical Uses. The Ninth Rinshoken International Conference, Nov. 28-30, Tokyo, Japan, Abstr. 25.
40. Siesjö B.K. Pathophysiology and treatment of focal cerebral ischemia: Part II. Mechanisms of damage and treatment. J. Neurosurgery. 77:1992;337-354.
41. Simonian N.A., Getz R.L., Leveque J.C., Konradi C., Coyle J.T. Kainate induced apoptosis in neurons. Neuroscience. 74:1996;675-683.
42. Sweeney M.I. Neuroprotective effects of adenosine in cerebral ischemia: window of opportunity. Neurosci. Biobehav. Rev. 21:1997;207-217.
43. Theriault, E., 1997. US Patent 5,607973.
44. Turetsky D.M., Buisson A., Choi D.W. The metabotropic glutamate receptor agonist, 4C3HPG, reduces kainate-induced death of cortical neurons expressing calcium-permeable AMPA/kainate receptors. Soc. Neurosci. Abstr. 21:1995;529.20.
45. Winder D.G., Conn P.J. Activation of metabotropic glutamate receptor increases cAMP accumulation in hippocampus by potentiating responses to endogenous adenosine. J. Neurosci. 13:1993;38-44.
46. Winder D.G., Conn P.J. Metabotropic glutamate receptor (mGluR)-mediated potentiation of cyclic AMP responses does not require phosphoinositide hydrolysis: mediation by a group II-like mGluR. J. Neurochem. 64:1995;592-599.
47. Wu S., Wright R.A., Rockey P.K., Burgett S.G., Arnold P.R., Johnson B.G., Schoepp D.D., Belagaje R. Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression and comparison of pharmacological properties in RGT cells. Mol. Brain Res. 53:1998;88-97.